Organization · Venture Capital
dRx Capital
dRx Capital is a healthcare-focused investment organization based in Switzerland, specializing in digital health companies that leverage technology to enhance healthcare delivery and patient outcomes. The fund is backed by Novartis and Qualcomm Ventures.
Overview
What dRx Capital does
What dRx Capital is
dRx Capital is a healthcare-focused investment organization based in Switzerland, specializing in digital health companies that leverage technology to enhance healthcare delivery and patient outcomes. The fund is backed by Novartis and Qualcomm Ventures.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2015
- Approximate age
- About 11 years
- Structured capabilities
- Funder
- Last reviewed
- March 27, 2026
Official channels
Find dRx Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
dRx Capital as a funder
Investment thesis
dRx Capital focuses on the convergence of information technology and healthcare, investing in digital health companies that leverage technology to improve healthcare delivery and patient outcomes.
Focus narrative
dRx Capital targets early to growth-stage companies in the digital health sector, focusing on those that leverage AI, big data, and technology to optimize patient care and healthcare delivery. The organization operates primarily in Europe and North America, seeking to invest in companies that can integrate into the corporate ecosystems of its backers, Novartis and Qualcomm.
Value beyond capital
dRx Capital adds value to its portfolio companies through the strategic resources and expertise of its corporate backers, Novartis and Qualcomm. This includes access to clinical networks, regulatory expertise, and advanced technology capabilities, enabling portfolio companies to scale effectively and integrate into existing healthcare systems.
Terms and economics
- Typical check
- $1,000,000–$5,000,000
- Sweet spot
- $3,000,000
Focus and fit
- Stages
- Series A · Series B · Series C · Growth Equity
- Regions
- EuropeNorth America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 20
- Recorded notable exits
- SomaLogic
Portfolio context
Notable portfolio companies include: CureMetrix: Uses AI to improve mammography readings. Sana Health: Develops digital therapeutics for chronic pain management. Omada Health: Focuses on digital chronic disease management. Freenome: Specializes in AI cancer screening. SomaLogic: Engages in proteomics and biomarker discovery, went public via SPAC.
Common questions
What to know about dRx Capital
Upseed classifies dRx Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 27, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.